Compare Cipla with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SUN PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SUN PHARMA CIPLA/
SUN PHARMA
 
P/E (TTM) x 35.6 133.5 26.7% View Chart
P/BV x 4.1 3.1 135.1% View Chart
Dividend Yield % 0.5 0.7 71.2%  

Financials

 CIPLA   SUN PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-20
SUN PHARMA
Mar-20
CIPLA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs586484 120.9%   
Low Rs357315 113.2%   
Sales per share (Unadj.) Rs207.0136.9 151.3%  
Earnings per share (Unadj.) Rs18.617.5 106.6%  
Cash flow per share (Unadj.) Rs33.226.0 127.5%  
Dividends per share (Unadj.) Rs4.004.00 100.0%  
Dividend yield (eoy) %0.81.0 84.8%  
Book value per share (Unadj.) Rs195.5188.7 103.6%  
Shares outstanding (eoy) m806.352,399.26 33.6%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.32.9 77.9%   
Avg P/E ratio x25.322.9 110.6%  
P/CF ratio (eoy) x14.215.4 92.4%  
Price / Book Value ratio x2.42.1 113.8%  
Dividend payout %21.522.9 93.8%   
Avg Mkt Cap Rs m379,912958,864 39.6%   
No. of employees `00025.817.8 145.5%   
Total wages/salary Rs m30,27063,624 47.6%   
Avg. sales/employee Rs Th6,459.618,490.6 34.9%   
Avg. wages/employee Rs Th1,171.23,582.6 32.7%   
Avg. net profit/employee Rs Th580.22,357.6 24.6%   
INCOME DATA
Net Sales Rs m166,949328,375 50.8%  
Other income Rs m3,4426,360 54.1%   
Total revenues Rs m170,391334,735 50.9%   
Gross profit Rs m32,06069,898 45.9%  
Depreciation Rs m11,74720,528 57.2%   
Interest Rs m1,9743,027 65.2%   
Profit before tax Rs m21,78252,702 41.3%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m6,3128,228 76.7%   
Profit after tax Rs m14,99541,868 35.8%  
Gross profit margin %19.221.3 90.2%  
Effective tax rate %29.015.6 185.6%   
Net profit margin %9.012.8 70.4%  
BALANCE SHEET DATA
Current assets Rs m117,038316,542 37.0%   
Current liabilities Rs m43,931157,064 28.0%   
Net working cap to sales %43.848.6 90.2%  
Current ratio x2.72.0 132.2%  
Inventory Days Days9688 109.3%  
Debtors Days Days85105 81.2%  
Net fixed assets Rs m107,424243,102 44.2%   
Share capital Rs m1,6132,399 67.2%   
"Free" reserves Rs m156,018450,245 34.7%   
Net worth Rs m157,630452,645 34.8%   
Long term debt Rs m23,69320,289 116.8%   
Total assets Rs m236,626682,525 34.7%  
Interest coverage x12.018.4 65.4%   
Debt to equity ratio x0.20 335.3%  
Sales to assets ratio x0.70.5 146.6%   
Return on assets %7.26.6 109.0%  
Return on equity %9.59.2 102.8%  
Return on capital %12.811.2 114.3%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,03674,219 75.5%   
Fx outflow Rs m6,76427,964 24.2%   
Net fx Rs m49,27246,255 106.5%   
CASH FLOW
From Operations Rs m30,68565,548 46.8%  
From Investments Rs m1,040-25,888 -4.0%  
From Financial Activity Rs m-29,488-57,151 51.6%  
Net Cashflow Rs m2,340-13,857 -16.9%  

Share Holding

Indian Promoters % 16.0 63.7 25.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.1 237.8%  
FIIs % 23.7 23.0 103.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 8.3 315.7%  
Shareholders   161,166 133,026 121.2%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   AJANTA PHARMA  GLENMARK PHARMA  NEULAND LABS  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 22, 2021 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS